Trial Profile
Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Intermediate Risk Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs Padeliporfin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Steba Biotech
- 13 Sep 2021 Results presented at the 116th Annual Meeting of the American Urological Association
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 18 Mar 2021 Planned End Date changed from 22 Oct 2024 to 2 Nov 2024.